Compare Cipla with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 29.4 17.2 171.3% View Chart
P/BV x 4.2 3.7 111.9% View Chart
Dividend Yield % 0.5 0.3 173.6%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
AUROBINDO PHARMA
Mar-19
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs586830 70.5%   
Low Rs357527 67.7%   
Sales per share (Unadj.) Rs207.0333.9 62.0%  
Earnings per share (Unadj.) Rs18.640.4 46.1%  
Cash flow per share (Unadj.) Rs33.251.8 64.1%  
Dividends per share (Unadj.) Rs4.002.50 160.0%  
Dividend yield (eoy) %0.80.4 230.4%  
Book value per share (Unadj.) Rs195.5237.1 82.5%  
Shares outstanding (eoy) m806.35585.91 137.6%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.0 112.0%   
Avg P/E ratio x25.316.8 150.7%  
P/CF ratio (eoy) x14.213.1 108.4%  
Price / Book Value ratio x2.42.9 84.2%  
Dividend payout %21.56.2 347.2%   
Avg Mkt Cap Rs m379,912397,569 95.6%   
No. of employees `00025.817.9 144.7%   
Total wages/salary Rs m30,27025,849 117.1%   
Avg. sales/employee Rs Th6,459.610,956.9 59.0%   
Avg. wages/employee Rs Th1,171.21,447.7 80.9%   
Avg. net profit/employee Rs Th580.21,324.3 43.8%   
INCOME DATA
Net Sales Rs m166,949195,636 85.3%  
Other income Rs m3,4421,553 221.6%   
Total revenues Rs m170,391197,189 86.4%   
Gross profit Rs m32,06039,519 81.1%  
Depreciation Rs m11,7476,680 175.9%   
Interest Rs m1,9742,626 75.2%   
Profit before tax Rs m21,78231,767 68.6%   
Minority Interest Rs m-47527 -1,757.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m6,3127,269 86.8%   
Profit after tax Rs m14,99523,645 63.4%  
Gross profit margin %19.220.2 95.1%  
Effective tax rate %29.022.9 126.7%   
Net profit margin %9.012.1 74.3%  
BALANCE SHEET DATA
Current assets Rs m117,038153,645 76.2%   
Current liabilities Rs m43,931120,429 36.5%   
Net working cap to sales %43.817.0 257.9%  
Current ratio x2.71.3 208.8%  
Inventory Days Days96135 70.8%  
Debtors Days Days8564 133.6%  
Net fixed assets Rs m107,424103,909 103.4%   
Share capital Rs m1,613586 275.2%   
"Free" reserves Rs m156,018138,322 112.8%   
Net worth Rs m157,630138,908 113.5%   
Long term debt Rs m23,6931,800 1,316.6%   
Total assets Rs m236,626264,544 89.4%  
Interest coverage x12.013.1 91.9%   
Debt to equity ratio x0.20 1,160.3%  
Sales to assets ratio x0.70.7 95.4%   
Return on assets %7.29.9 72.2%  
Return on equity %9.517.0 55.9%  
Return on capital %12.823.8 53.9%  
Exports to sales %33.049.6 66.6%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs m55,17597,091 56.8%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m56,03697,316 57.6%   
Fx outflow Rs m6,76440,589 16.7%   
Net fx Rs m49,27256,727 86.9%   
CASH FLOW
From Operations Rs m30,68516,220 189.2%  
From Investments Rs m1,040-28,768 -3.6%  
From Financial Activity Rs m-29,48819,191 -153.7%  
Net Cashflow Rs m2,3406,656 35.2%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tumbles 600 Points Tracking Global Selloff; HDFC & Tata Steel Top Losers(09:30 am)

A fresh spike in US bond yields and a firm dollar triggered a selloff in Asian share markets today.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Mar 4, 2021 12:16 PM

TRACK CIPLA

CIPLA - DIVIS LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS